INZY vs. ARDX

In the year-to-date period, INZY achieves a -29.81% return, which is significantly lower than ARDX's -22.26% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Inozyme Pharma, Inc. (INZY) and Ardelyx, Inc. (ARDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current INZY Sharpe Ratio is -0.38, which is lower than the ARDX Sharpe Ratio of -0.23. The chart below compares the historical Sharpe Ratios of INZY and ARDX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither INZY nor ARDX has paid dividends to shareholders.

The maximum INZY drawdown since its inception was -96.52%, roughly equal to the maximum ARDX drawdown of -98.45%. Use the drawdown chart below to compare losses from any high point for INZY and ARDX. For additional features, visit the drawdowns tool.

Inozyme Pharma, Inc. (INZY) and Ardelyx, Inc. (ARDX) have volatilities of 20.95% and 20.53%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Inozyme Pharma, Inc. and Ardelyx, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.